Boston pharmaceutical company Alexion agreed to a $21 million settlement with the Securities and Exchange Commission regarding allegations that it violated the Foreign Corrupt Practices Act regulations in its dealings via subsidiaries in Turkey and Russia.
The SEC alleged that Alexion subsidiaries in Turkey made payments to foreign officials for favorable regulatory treatment for Alexion’s main drug Solaris, and subsidiaries in Russia made payments to foreign officials to influence regional health care budgets for Solaris.
